BrightPath Biotherapeutics Co.Ltd. (JP:4594)

:4594

4594

BrightPath Biotherapeutics Co.Ltd.

RESEARCH TOOLSreports

Want to see JP:4594 full AI Analyst Report?

BrightPath Biotherapeutics Co.Ltd. (4594) Price & Analysis

0 Followers

4594 Stock Chart & Stats

¥48.00

¥1.00(2.27%)

At close: Jan 08 4:00 PM EST

¥48.00

¥1.00(2.27%)

Day’s Range― - ―

52-Week Range¥38.00 - ¥114.00

Previous CloseN/A

Volume188.00K

Average Volume (3M)2.78M

Market Cap

¥8.19B

Enterprise Value¥4.24B

Total Cash (Recent Filing)¥1.30B

Total Debt (Recent Filing)¥500.00M

Price to Earnings (P/E)―

Beta1.03

Next Earnings

May 14, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-19.27

Shares Outstanding138,891,300

10 Day Avg. Volume4,086,650

30 Day Avg. Volume2,782,203

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)3.88

Price to Sales (P/S)3165.29

P/FCF Ratio-2.87

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Rapid Revenue GrowthA >10x reported revenue increase indicates strong commercial traction or milestone-driven receipts. Such material top-line expansion can create lasting operational scale, improve bargaining power with suppliers, and provide a base to leverage fixed R&D costs as the business commercializes products.

Improving Gross MarginAn improved gross margin shows the company is capturing more value per unit of revenue, signaling early operating leverage. For a biotech moving from development to commercialization, sustained margin improvement supports a credible path toward positive EBITDA as revenues scale.

Conservative Capital StructureA strong equity ratio and low leverage give the firm financial flexibility to fund R&D cycles and absorb setbacks without immediate default risk. This conservative balance sheet is a durable strength in capital-intensive biotech where access to capital can be episodic.

Bears Say

Persistent Net LossesSustained losses across EBIT, EBITDA and net income indicate the business has not yet achieved operational profitability. Over the medium term, continued negative results can erode equity, constrain reinvestment in pipelines, and force strategic trade-offs that impair long-term value creation.

Negative Operating & Free Cash FlowOngoing negative operating and free cash flow mean the company is not funding operations internally. This structural cash burn increases reliance on external capital, raises dilution or covenant risk, and limits the firm’s ability to self-fund late-stage trials or commercialization efforts.

Reliance On Financing To Bridge DeficitsDependence on financing cash inflows to cover deficits creates execution and financing risk. In biotechnology, intermittent funding needs can lead to costly capital raises or dilution and may force reprioritization of programs if market access tightens, creating a persistent strategic vulnerability.

4594 FAQ

What was BrightPath Biotherapeutics Co.Ltd.’s price range in the past 12 months?

BrightPath Biotherapeutics Co.Ltd. lowest stock price was ¥38.00 and its highest was ¥114.00 in the past 12 months.

What is BrightPath Biotherapeutics Co.Ltd.’s market cap?

BrightPath Biotherapeutics Co.Ltd.’s market cap is ¥8.19B.

When is BrightPath Biotherapeutics Co.Ltd.’s upcoming earnings report date?

BrightPath Biotherapeutics Co.Ltd.’s upcoming earnings report date is May 14, 2026 which is in 10 days.

How were BrightPath Biotherapeutics Co.Ltd.’s earnings last quarter?

BrightPath Biotherapeutics Co.Ltd. released its earnings results on Feb 13, 2026. The company reported -¥4.54 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.54.

Is BrightPath Biotherapeutics Co.Ltd. overvalued?

According to Wall Street analysts BrightPath Biotherapeutics Co.Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does BrightPath Biotherapeutics Co.Ltd. pay dividends?

BrightPath Biotherapeutics Co.Ltd. does not currently pay dividends.

What is BrightPath Biotherapeutics Co.Ltd.’s EPS estimate?

BrightPath Biotherapeutics Co.Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does BrightPath Biotherapeutics Co.Ltd. have?

BrightPath Biotherapeutics Co.Ltd. has 138,891,300 shares outstanding.

What happened to BrightPath Biotherapeutics Co.Ltd.’s price movement after its last earnings report?

BrightPath Biotherapeutics Co.Ltd. reported an EPS of -¥4.54 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.286%.

Which hedge fund is a major shareholder of BrightPath Biotherapeutics Co.Ltd.?

Currently, no hedge funds are holding shares in JP:4594

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

BrightPath Biotherapeutics Co.Ltd.

BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. In addition, the company offers induced pluripotent stem cell derived regenerated NKT cell therapy for head and neck cancer; and BP2301, an autologous HER2 chimeric antigen receptor-T cell therapy for treating solid tumors sarcoma. Further, it is involved in discovering BP1200, an antibody targeting CD73; BP1210, an immune checkpoint inhibitory antibody; and other antibodies, such as BP1202, BP1206, and BP1211. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. BrightPath Biotherapeutics Co., Ltd. was founded in 2003 and is headquartered in Tokyo, Japan.